Mathilde Allard

Mathilde Allard

Auto-generated profile, based on publicly available information

Mathilde Allard

Université d’Angers, CRCI2NA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SMSilvia A. Fuertes Marraco
Silvia A. Fuertes Marraco
CSCharlotte Soneson
Charlotte Soneson
LCLaurène Cagnon
Laurène Cagnon
PGPhilippe O. Gannon
Philippe O. Gannon
MAMathilde Allard
Mathilde Allard
DSDaniel Speiser
Daniel Speiser
The yellow fever vaccine induces a CD8+T stem cell–like memory subset with a naïve-like profile that persists long term.

3 May 2019 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
DMDenis Migliorini
Denis Migliorini
VDValérie Dutoit
Valérie Dutoit
MAMathilde Allard
Mathilde Allard
NHNicole Grandjean Hallez
Nicole Grandjean Hallez
EMEliana Marinari
Eliana Marinari
PDPierre-Yves Dietrich
Pierre-Yves Dietrich
Peptide vaccines offer the opportunity to elicit glioma-specific T cells with tumor killing ability. Using antigens eluted from the surface of glioblastoma samples, we designed a phase I/II study to test safety and immunogenicity of the IMA950 multipeptide vaccine adjuvanted with poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose) in human leukocyte antigen A2+ glioma patients. Adult patients with newly diagnosed glioblastoma (n = 16) and grade III astrocytoma (n = 3) were treated with radiochemotherapy followed by IMA950/poly-ICLC vaccination. The first 6 patients received IMA950 (9 major histocompatibility complex [MHC] class I and 2 MHC class II peptides) intradermally and poly-ICLC intramuscularly (i.m.). After protocol amendment, IMA950 and poly-ICLC were mixed and injected subcutaneously (n = 7) or i.m. (n = 6). Primary endpoints were safety and immunogenicity. Secondary endpoints were overall survival, progression-free survival at 6 and 9 months, and vaccine-specific peripheral cluster of differentiation (CD)4 and CD8 T-cell responses. The IMA950/poly-ICLC vaccine was safe and well tolerated. Four patients presented cerebral edema with rapid recovery. For the first 6 patients, vaccine-induced CD8 T-cell responses were restricted to a single peptide and CD4 responses were absent. After optimization of vaccine formulation, we observed multipeptide CD8 and sustained T helper 1 CD4 T-cell responses. For the entire cohort, CD8 T-cell responses to a single or multiple peptides were observed in 63.2% and 36.8% of patients, respectively. Median overall survival was 19 months for glioblastoma patients. We provide, in a clinical trial, using cell surface-presented antigens, insights into optimization of vaccines generating effector T cells for glioma patients. Clinicaltrials.gov NCT01920191.

1 August 2019 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
MTMarta Calvo Tardón
Marta Calvo Tardón
MAMathilde Allard
Mathilde Allard
VDValérie Dutoit
Valérie Dutoit
PDPierre-Yves Dietrich
Pierre-Yves Dietrich
PWPaul R Walker
Paul R Walker

18 November 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MHMichael Hebeisen
Michael Hebeisen
MAMathilde Allard
Mathilde Allard
PGPhilippe O. Gannon
Philippe O. Gannon
JSJulien Schmidt
Julien Schmidt
DSDaniel Speiser
Daniel Speiser
NRNathalie Rufer
Nathalie Rufer
Cytotoxic T cells recognize, via their T cell receptors (TCRs), small antigenic peptides presented by the Major Histocompatibility Complex (pMHC) on the surface of professional antigen presenting cells (APC), and infected or malignant cells. The efficiency of T cell triggering critically depends on TCR binding to cognate pMHC, i.e. the TCR-pMHC structural avidity. The binding and kinetic attributes of this interaction are key parameters for protective T cell-mediated immunity, with stronger TCR-pMHC interactions conferring superior T cell activation and responsiveness than weaker ones. However, high avidity TCRs are not always available, particularly among self/tumor antigen-specific T cells, most of which are eliminated by central and peripheral deletion mechanisms. Consequently, systematic assessment of T cell avidity can greatly help distinguishing protective from non-protective T cells. Here, we review novel strategies to assess TCR-pMHC interaction kinetics, enabling the identification of the functionally most-relevant T cells. We also discuss the significance of these technologies in determining which cells within a naturally occurring polyclonal tumor-specific T cell response would offer the best clinical benefit for use in adoptive therapies, with or without T cell engineering.

15 November 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
DPDanilo Presotto
Danilo Presotto
EEEfe Erdes
Efe Erdes
MDMinh Ngoc Duong
Minh Ngoc Duong
MAMathilde Allard
Mathilde Allard
PRPierre-Olivier Regamey
Pierre-Olivier Regamey
MHMichael Hebeisen
Michael Hebeisen
Redirecting CD8 T cell immunity with self/tumor-specific affinity-matured T cell receptors (TCRs) is a promising approach for clinical adoptive T cell therapy, with the aim to improve treatment efficacy. Despite numerous functional-based studies, little is known about the characteristics of TCR signaling (i.e., intensity, duration, and amplification) and the regulatory mechanisms underlying optimal therapeutic T cell responses. Using a panel of human SUP-T1 and primary CD8 T cells engineered with incremental affinity TCRs against the cancer-testis antigen NY-ESO-1, we found that upon activation, T cells with optimal-affinity TCRs generated intense and sustained proximal (CD3ζ, LCK) signals associated with distal (ERK1/2) amplification-gain and increased function. In contrast, in T cells with very high affinity TCRs, signal initiation was rapid and strong yet only transient, resulting in poor MAPK activation and low proliferation potential even at high antigen stimulation dose. Under resting conditions, the levels of surface TCR/CD3ε, CD8β, and CD28 expression and of CD3ζ phosphorylation were significantly reduced in those hyporesponsive cells, suggesting the presence of TCR affinity-related activation thresholds. We also show that SHP phosphatases were involved along the TCR affinity gradient, but displayed spatially distinct regulatory roles. While PTPN6/SHP-1 phosphatase activity controlled TCR signaling initiation and subsequent amplification by counteracting CD3ζ and ERK1/2 phosphorylation, PTPN11/SHP-2 augmented MAPK activation without affecting proximal TCR signaling. Together, our findings indicate that optimal TCR signaling can be finely tuned by TCR affinity-dependent SHP-1 and SHP-2 activity, and this may readily be determined at the TCR/CD3 complex level. We propose that these TCR affinity-associated regulations represent potential protective mechanisms preventing high affinity TCR-mediated autoimmune diseases.

21 June 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMathilde Allard
Mathilde Allard
RORomain Oger
Romain Oger
VVVirginie Vignard
Virginie Vignard
JPJean-Michel Percier
Jean-Michel Percier
GFGiulia Fregni
Giulia Fregni
NGNadine Gervois
Nadine Gervois
Tumor-derived soluble factors, including soluble HLA molecules, can contribute to cancer immune escape and therefore impact on clinical course of malignant diseases. We previously reported that melanoma cells produce, in vitro, soluble forms of the non-classical MHC class I molecule HLA-E (sHLA-E). In order to investigate sHLA-E production by various tumors and to address its potential value as a tumor-associated marker, we developed a specific ELISA for the quantification of sHLA-E in biological fluids. We developed a sHLA-E specific and sensitive ELISA and we showed that serum sHLA-E levels were significantly elevated (P<0.01) in melanoma patients (n = 127), compared with healthy donors (n = 94). sHLA-E was also detected in the culture supernatants of a wide variety of tumor cell lines (n = 98) including melanomas, kidney, colorectal and breast cancers. Cytokines regulation of sHLA-E production by tumor cells was also carried out. IFN-γ, IFN-α and TNF-α were found to upregulate sHLA-E production by tumor cells. In view of the broad tumor tissue release of HLA-E and its up-regulation by inflammatory cytokines, sHLA-E should be studied for its involvement in immune responses against tumors. Interestingly, our results demonstrated a positive association between the presence of serum sHLA-E and melanoma. Therefore, the determination of sHLA-E levels, using ELISA approach, may be investigated as a clinical marker in cancer patients.